Exploring a novel therapeutic target in cystic fibrosis

PRINCIPAL INVESTIGATOR:
Dr. Anita Balazs
Charite

SUMMARY

Cystic Fibrosis (CF) is a life-limiting disease caused by mutations in the CFTR gene. Although highly effective CFTR modulators are emerging, ~10-15% of patients will not benefit from these therapies, while the high price of these drugs prevents access in many countries. Hence, there is an unmet need to develop new therapies that can be applied to patients, independently of the underlying CFTR mutation. A strategy to achieve this, relies on restoring epithelial ion transport, bypassing CFTR dysfunction. This project aims to validate drug candidates previously identified in a drug screen as potential modulators of an alternative ion transporter. These potential hits may path the way for a novel and inclusive therapy for CF.

PROJECT ACHIEVEMENTS DURING & AFTER SPARK

- in vitro functional studies with selected hits
- Further analysis of mechanism of action

LONG-TERM GOALS

- Show in vivo PoC
- Perform clinical testing
- License to Pharma